Status: Not yet recruiting

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Participants needed: 48

Trial details

Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Updated: May 5, 2026Locations: 7

Eligibility criteria

Subjects who can fully understand this trial and voluntarily sign the informed c... [+6]

Primary central nervous system (CNS) lymphoma; However, secondary CNS lymphoma w... [+14]

Status: Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.

Participants needed: 33

Trial details

Phase: Phase 1Age: 3-25Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Updated: May 22, 2025Locations: 8

Eligibility criteria

The patient himself/herself , and/or his/her legal guardian, agree to participat... [+2]

Active CNS involvement by malignancy； [+3]

Clinical trials

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.